

Oregon Prescription Drug Monitoring Program 2021 2nd Quarter Report


Percentage change evaluated relative to 2nd Quarter, 2020

healthoregon.org/pdmp



Summary

- Integrated queries have increased 74.8% and web queries have increased by 2.1% from the 2nd quarter of 2020 (Table 1).
- Prescriptions for amphetamine (+ 19.8 %) and methylphenidate (+ 13.3 %) have increased the most since 2020 Q2 relative to the rest of the most commonly prescribed controlled substances (Table 5).
- Registration has increased for all user disciplines, but especially for NDs (+ 145%).
- Percent changes included in this report should be interpreted with caution since the comparison quarter (2020 Q2) was during the beginning of the COVID-19 pandemic in the United States, where many aspects of medical care were different.
- 22.8% of opioid prescribers this quarter were responsible for at least one prescription of over 90 morphine milligram equivalents (calculated as 23.8% for the first time in 2021 Q1).[#]



[#] Revised on 2021-12-14 from an earlier report.

(Note: Report updated August 2022 to reflect more accurate query count.)

Oregon Prescription Drug Monitoring Program
2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020

healthoregon.org/pdmp



Table 1. PDMP Queries Summary Statistics: April-June, 2021

Measure	Web Portal	% Change*	Integrated	% Change*
Queries †	298,960	+2.1%	7,670,043	+74.8%
Healthcare providers	80,334	+5.2%	6,649,013	+84.6%
Pharmacies	60,157	-14.4%	1,021,030	+29.8%
Delegates	158,275	+8.4%	-	-

- Web Portal queries increased slightly from the same quarter last year across most user groups.
- The number of integrated queries continues to increase.
- Percent changes of integrated queries may be especially large because queries were low during COVID-19 lockdowns in 2020 Q2.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

Table 2. Special Requests: April-June, 2021

Measure	Count
Special Requests Total	95
Patient Records	17
Healthcare Board	68
Law Enforcement	10

- 95 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.
- Request numbers appear to have rebounded after decreases seen during the COVID-19 pandemic.

* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWARe web portal, the PMPi Gateway audit file and the EDIE supplementary audit file.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

(Note: Report updated August 2022 to reflect more accurate query count.)

Oregon Prescription Drug Monitoring Program 2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020

healthoregon.org/pdmp



Table 3. PDMP Enrollment and System Use: April-June, 2021

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
All Prescribers (by DEA)*	18,364	15,637 / 85.2 %	5,294 / 33.9 %	11,326 / 72.4 %	12,633 / 80.8 %
Top 4K Prescribers	4,000	3,865 / 96.6 %	2,174 / 88.5 %	3,419 / 88.5 %	3,666 / 94.9 %
Top 2K Prescribers	2,000	1,954 / 97.7 %	1,206 / 61.7 %	1,748 / 89.5 %	1,863 / 95.3 %

- During the 2nd quarter of 2021 there were 18,364 prescribers who wrote prescriptions for controlled substances in Oregon.
- At the close of the 2nd quarter, 80.8 % of enrolled prescribers queried the system; 94.9 % of the top 4,000 prescribers; 95.3 % of the top 2,000 prescribers through the web portal or integration.
- The percentage of enrolled prescribers who queried the system is much higher than the second quarter of 2020, when only 48.4% queried the system. This may have occurred due to a reduced number of appointments related to the COVID-19 pandemic.

Table 4. PDMP Query by Clinical User Group: April-June, 2021

Discipline	Total User Accounts (by DEA)*	% Change*	Web Users ^{±†}	% Change*	Integrated Users	% Change*
MD/PA/DO	18,797	+ 10.2 %	1,786	- 4.9 %	12,943	- 23.1 %
NP/CNS-PP	5,012	+ 26.1 %	958	+ 1.8 %	3,027	+ 262.9 %
RPh	4,141	+ 10.3 %	1,459	- 7.9 %	352	- 49.3%
Delegates	3,800	+ 13.4 %	1,893	- 7.3 %	-	-
DDS/DMD	3,612	+ 26.6 %	409	- 7.9 %	252	+ 460.0 %
ND	1,446	+ 145.9 %	151	- 3.2 %	433	+ 1,212.1 %

- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is generally decreasing, while integrated users are mostly increasing.
- Percent change in query numbers may be especially high due to low querying in the comparison quarter that was associated with changes in medical practices due to COVID-19.

* Prescriber counts provided by unique DEA Number. Please note some providers may be associated with multiple DEA numbers.

* Percentage change figures evaluated relative to the same time period during the prior year.

± Users that have submitted a query this quarter.

† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

(Note: Report updated August 2022 to reflect more accurate query count.)

Oregon Prescription Drug Monitoring Program
2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020

healthoregon.org/pdmp



Table 5. Top Prescriptions: April-June, 2021

Drug	# of Rx	% of all Rx	% Change*
All	1,698,502	100.0 %	+ 7.5 %
Hydrocodone	244,976	14.4 %	+ 5.6 %
Oxycodone	231,994	13.7 %	+ 13.6 %
Gabapentin	229,801	13.5 %	+ 5.7 %
Amphetamine	169,762	10.0 %	+ 19.8 %
Lorazepam	83,571	4.9 %	+ 3.7 %
Tramadol	83,064	4.9 %	+ 1.4 %
Methylphenidate	74,625	4.4 %	+ 13.3 %
Zolpidem	66,126	3.9 %	- 3.5 %
Alprazolam	60,864	3.6 %	- 1.5 %
Clonazepam	60,436	3.6 %	-2.0 %

- Prescriptions for stimulants (i.e., amphetamine, methylphenidate) increased relative to the same quarter last year.
- Oxycodone and hydrocodone prescriptions increased.
- The number of prescriptions for some commonly prescribed benzodiazepines decreased (i.e., alprazolam, clonazepam), but not for lorazepam (+ 3.7 %).
- Prescriptions for gabapentin increased, reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.

Table 6. Prescriptions for Buprenorphine and Naloxone: April-June, 2021

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	22,051	1.3 %	- 39.8 %
Buprenorphine/Naloxone	10,365	0.6 %	- 56.1 %
Naloxone	5,888	0.3 %	+ 39.3 %

- Prescriptions for naloxone have increased while prescriptions for buprenorphine and buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, pdmp.research@state.or.us

* Percentage change figures evaluated relative to the same time period during the prior year.
(Note: Report updated August 2022 to reflect more accurate query count.)